Actonel and Second primary malignancy - a phase IV clinical study of FDA data

Summary:

Second primary malignancy is reported as a side effect among people who take Actonel (risedronate sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Second primary malignancy when taking Actonel. It is created by eHealthMe based on reports of 28,929 people who have side effects when taking Actonel from the FDA, and is updated regularly.

What is Actonel?

Actonel has active ingredients of risedronate sodium. It is often used in osteoporosis. eHealthMe is studying from 29,369 Actonel users. Check the latest studies of Actonel.

What is Second primary malignancy?

Second primary malignancy (after getting cure a cancer, a new cancer development) is found to be associated with 565 drugs and 464 conditions by eHealthMe. Check the latest studies of Second primary malignancy.

On Mar, 13, 2026

28,929 people reported to have side effects when taking Actonel.
Among them, 12 people (0.04%) have Second primary malignancy.

Could Actonel cause Second primary malignancy?

Among these 12 people:

How long have people been on Actonel when they have Second primary malignancy? *

What is the gender of people who have Second primary malignancy when taking Actonel? *

female: 75 %
male: 25 %

What is the age of people who have Second primary malignancy when taking Actonel? *

What are other drugs people take besides Actonel? *

What are other side effects people have besides Second primary malignancy? *

Pain: 7 people, 58.33%
Osteonecrosis Of Jaw (death of bone of jaw): 7 people, 58.33%
Spinal Osteoarthritis (joint cartilage loss in spine): 6 people, 50.00%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 6 people, 50.00%
Memory Loss: 6 people, 50.00%
Bone Pain: 6 people, 50.00%
Hypokalemia (low potassium): 6 people, 50.00%
Anaemia (lack of blood): 6 people, 50.00%
Depression: 6 people, 50.00%
Stress And Anxiety: 6 people, 50.00%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 4 people, 33.33%
Breast Cancer: 3 people, 25.00%
Multiple Myeloma (cancer of the plasma cells): 3 people, 25.00%
Lung Cancer - Non-Small Cell (lung cancer): 3 people, 25.00%
Birth Control: 2 people, 16.67%
Breast Cancer Female: 2 people, 16.67%
Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 2 people, 16.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 16.67%
Rickets (softening of bones): 1 person, 8.33%
Cystitis Interstitial (unknown cause characterized by bladder pain): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Actonel and have Second primary malignancy?

- Check whether Second primary malignancy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Actonel:

Actonel (29,369 reports)

Browse all side effects of Actonel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Second primary malignancy:

Second primary malignancy (565 drugs)

Browse all the conditions that are associated with Second primary malignancy:

Second primary malignancy (464 conditions)

Related publications that referenced our studies

Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .
Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on risedronate sodium (the active ingredients of Actonel) and Actonel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.